Not medical advice. A record of published research and our assessments of it. The limits

Studies

Every study, review and regulatory document in the collection, newest first. Each links to a page with its population, findings, funding and original source.

01Find

Filter studies

Search titles and summaries

Population match

Topic

Drug

Design

Study tier

Outcome type

Direction

Explained by weight loss?

Industry funded

Peer reviewed

Published from year

Clear filters

5 studies · Download as JSON

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney DiseaseAnimal study · 2026 · Facts auto-extracted
Survodutide Once Weekly in Adults with Obesity and Type 2 DiabetesRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agentsPharmacovigilance · 2026 · Facts auto-extracted
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear